How to Buy Scholar Rock Holding Stock
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Scholar Rock Holding stock last closed at $47.95, up 2.87% from the previous day, and has increased 19.73% in one year. It has overperformed other stocks in the Biotechnology industry by 0.51 percentage points. Scholar Rock Holding stock is currently +111.14% from its 52-week low of $22.71, and -3.75% from its 52-week high of $49.82.
There are currently 102.01M SRRK shares outstanding. The market capitalization of SRRK is $4.89B. In the last 24 hours, 1.01M SRRK shares were traded.
How to Buy Scholar Rock Holding Stock
Not sure how to invest in Scholar Rock Holding stock? Here's how.
- Decide where to buy Scholar Rock Holding stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you decide where to buy Scholar Rock Holding stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Choose your payment method and add your details.
- Analyze Scholar Rock Holding stock: The Scholar Rock Holding ticker symbol is SRRK. Is Scholar Rock Holding stock a good investment? Should you buy shares of SRRK? How do SRRK's underlying business fundamentals look? Do top analysts think Scholar Rock Holding is a good buy? Why has SRRK's stock price moved recently? (Hint: Our stock market research tools can help you evaluate if SRRK is a good stock to buy).
- Execute your SRRK purchase: Decide if you will purchase SRRK shares at the current market price or use a limit order to purchase SRRK shares at a specific price.
- Keep tabs on your SRRK investment: Create a watchlist to track your position in Scholar Rock Holding stock.
Step 1: Decide where to buy Scholar Rock Holding stock
You will need an online brokerage account to access the NASDAQ market and buy SRRK stock.
Our preferred brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Tech to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal information so you can invest in SRRK stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open your new brokerage account.
- Send your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've finished signing up on the best stock app to use, you need to deposit funds:
Check out this video walkthrough to see the process of depositing funds into your brokerage account.
Step 4: Analyze Scholar Rock Holding stock
Once you have figured out the best place to buy Scholar Rock Holding stock, it's very important to evaluate their stock prior to investing, so you truly comprehend the risk as well as the opportunity.
Scholar Rock Holding stock quick numbers
Scholar Rock Holding Overview
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on SRRK's stock page.
Is SRRK stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge SRRK's intrinsic value.
Using relative valuations measures:
- SRRK could be overvalued based on its P/B ratio of 19.96x, relative to Biotechnology industry P/B ratio of 5.26x
You can do additional valuation analysis on SRRK's stock here.
SRRK Financial Health
Positive Health Checks:
- SRRK has cash burn of 274644000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the SRRK balance sheet.
- Total SRRK debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the SRRK balance sheet.
Negative Health Checks:
- SRRK has $373.44M in cash and short term investments. This is not enough to cover its annual cash burn of $274.64M.
- SRRK has a relatively high debt to equity ratio of 0.68.
Is Scholar Rock Holding stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 10 Equities analysts who research SRRK, the consensus analyst rating on SRRK is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest SRRK Analyst Forecasts
Tessa Romero, a top 14% analyst from JP Morgan maintains SRRK with a strong buy rating and raises their SRRK price target from $46.00 to $47.00, on Nov 18, 2025.
JP Morgan's Tessa Romero raised their price target on Scholar Rock Holding (NASDAQ: SRRK) by 2.2% from $46 to $47 on 2025/11/18. The analyst maintained their Strong Buy rating on the stock.
Scholar Rock Holding reported its Q3 2025 earnings.
Following an assessment of the print, Romero said they revised their model and hiked their price target.
Earnings Report
For Q3 2025, Scholar Rock reported:
- Loss per share of $0.90, compared to Q3 2024’s loss per share of $0.66.
Management did not provide EPS and revenue guidance in its press release.
Chairman & CEO David L. Hallal commented: “We are unwavering in our commitment to bring apitegromab, the world’s first and only muscle-targeted treatment to improve motor function, to children and adults living with SMA.
“We are grateful to the FDA, Cure SMA, and our colleagues at Novo Nordisk for the positive engagement at our in-person Type A meeting earlier this week.
“We are encouraged by the discussion and by our shared understanding of the urgency to bring this important treatment to the SMA community as rapidly as possible.
“In parallel, we are equally focused on establishing Scholar Rock as the global leader in myostatin biology and muscle-targeted therapeutics, and we will continue to advance key strategic programs with tight financial discipline.”
Srikripa Devarakonda, a top 14% analyst from Truist Securities maintains SRRK with a strong buy rating and lowers their SRRK price target from $54.00 to $44.00, on Oct 20, 2025.
Tazeen Ahmad, a top 23% analyst from Bank of America initiates coverage on SRRK with a strong buy rating and announces their SRRK price target of $53.00, on Oct 9, 2025.
Allison Bratzel, a top 8% analyst from Piper Sandler maintains SRRK with a strong buy rating and lowers their SRRK price target from $52.00 to $51.00, on Sep 24, 2025.
Amy Li, a top 44% analyst from Jefferies assumes SRRK with a strong buy rating and announces their SRRK price target of $50.00, on Aug 21, 2025.
You can dive deeper into what analysts are saying on the Scholar Rock Holding stock forecast page.
SRRK Momentum
SRRK Growth Numbers
Last year, SRRK revenue was $0.00. Over the last five year, SRRK's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 43.37%.
Learn more about SRRK's earnings and revenue performance here.
What are SRRK insiders up to?
Over the last year, insiders at SRRK have bought more shares than they have sold.
Mo Qatanani, CHIEF SCIENTIFIC OFFICER of SRRK, was the latest SRRK insider to sell. They sold $97,187.94 worth of SRRK shares on Jan 22, 2026.
Dig into more about who owns SRRK shares here.
Does SRRK stock generate passive income?
No, Scholar Rock Holding doesn't provide an income stream by paying out dividends.
SRRK Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Execute your SRRK purchase
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a particular price limit, use a limit order.
Hit the Open button and eToro will place your order.
If you need additional assistance investing in stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your SRRK investment
Now that you own some SRRK shares, you'll want to stay up-to-date on your new company.
Start a watchlist to track the most important metrics related to your SRRK stock.
SRRK Feed
How to Buy Stock in Scholar Rock Holding
To reiterate, here are the 6 steps you need to take to buy Scholar Rock Holding stock right now:
- Decide where to buy Scholar Rock Holding stock
- Sign up for a brokerage account
- Put funds into your investment account
- Analyze Scholar Rock Holding stock
- Execute your SRRK purchase
- Keep tabs on your SRRK investment
If you require a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to monitor your investment in Scholar Rock Holding, add SRRK to your watchlist by clicking the button below.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.